FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

Phase 2

Terminated

Conditions: Sporadic Angiomyolipomas (AMLs)

Interventions: Drug: Everolimus

First Posted Date: 2015-09-03

Last Posted Date: 2022-12-15

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 20

Registration Number: NCT02539459

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 5 locations

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, T-Cell, Peripheral

Interventions: Drug: MK-3475
Drug: Copanlisib

First Posted Date: 2015-08-28

Last Posted Date: 2022-07-08

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 17

Registration Number: NCT02535247

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Perioperative Risk Study

Not Applicable

Active, not recruiting

Conditions: Primary Neoplasm
Surgery
Tumors
Secondary Neoplasm

Interventions: Other: Standard postoperative care
Other: Preoperative risk stratification
Other: Postoperative risk stratification
Other: Risk-based, escalating levels of care
Other: Risk-based, escalating levels of monitoring
Other: Risk-based, escalating levels of co-management

First Posted Date: 2015-05-28

Last Posted Date: 2025-04-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1456

Registration Number: NCT02456389

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2015-05-20

Last Posted Date: 2021-06-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 650

Registration Number: NCT02449213

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

Phase 1

Terminated

Conditions: Metastatic Renal Cell Carcinoma
RCC

Interventions: Drug: Ixazomib
Drug: Pegylated IFN-alpha 2b

First Posted Date: 2015-05-19

Last Posted Date: 2019-09-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT02447887

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Web-Based Multimedia Intervention for Head and Neck Cancer Patients

Not Applicable

Completed

Conditions: Cancer of the Head and Neck

Interventions: Behavioral: My Journey AHead

First Posted Date: 2015-05-13

Last Posted Date: 2021-03-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 80

Registration Number: NCT02442336

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients

Not Applicable

Completed

Conditions: Cancer of Pancreas

Interventions: Behavioral: Walking Intervention

First Posted Date: 2015-05-13

Last Posted Date: 2021-01-05

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 50

Registration Number: NCT02442323

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS)

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: PROGRESS

First Posted Date: 2014-08-25

Last Posted Date: 2021-10-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 431

Registration Number: NCT02224482

Locations: 🇺🇸
Icahn School of Medicine at Mt Sinai, New York, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Rutgers Cancer Insititute of New Jersey, Somerset, New Jersey, United States

Smoking Cessation for Low-Income Pregnant Women

Not Applicable

Completed

Conditions: Smoking
Pregnancy

Interventions: Behavioral: Best Practice (BC) Control
Behavioral: Cognitive-Behavioral Counseling (CBC)

First Posted Date: 2014-08-07

Last Posted Date: 2014-08-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 277

Registration Number: NCT02211430

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Carboplatin
Drug: Arsenic trioxide

First Posted Date: 2014-07-15

Last Posted Date: 2021-05-19

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 92

Registration Number: NCT02190695

Locations: 🇺🇸
Temple BMT Program at Jeanes Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy